Nervgen Pharma Corp Stock Current Valuation
| NGENF Stock | USD 1.85 0.06 3.35% |
Valuation analysis of NervGen Pharma Corp helps investors to measure NervGen Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that NervGen Pharma's price fluctuation is dangerous at this time. Calculation of the real value of NervGen Pharma Corp is based on 3 months time horizon. Increasing NervGen Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NervGen otc stock is determined by what a typical buyer is willing to pay for full or partial control of NervGen Pharma Corp. Since NervGen Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NervGen OTC Stock. However, NervGen Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.85 | Real 1.61 | Hype 1.85 | Naive 1.71 |
The real value of NervGen OTC Stock, also known as its intrinsic value, is the underlying worth of NervGen Pharma Corp OTC Stock, which is reflected in its stock price. It is based on NervGen Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NervGen Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NervGen Pharma Corp helps investors to forecast how NervGen otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NervGen Pharma more accurately as focusing exclusively on NervGen Pharma's fundamentals will not take into account other important factors: NervGen Pharma Corp OTC Stock Current Valuation Analysis
NervGen Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NervGen Pharma Current Valuation | 48.78 M |
Most of NervGen Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NervGen Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NervGen Pharma Corp has a Current Valuation of 48.78 M. This is 99.66% lower than that of the Healthcare sector and 98.95% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.71% higher than that of the company.
NervGen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in current valuation category among its peers.
NervGen Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Shares Owned By Insiders | 25.27 % | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Net Income | (12.73 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 4.25 X | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Beta | 1.7 | |||
| Market Capitalization | 87.43 M | |||
| Total Asset | 17.9 M | |||
| Net Asset | 17.9 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.